Document:

Exhibit
10.8

 

Execution
Copy

 

CONSULTING
AGREEMENT

 

THIS
CONSULTING AGREEMENT (this "Agreement") is made as of this 29 day of November (the "Effective Date"),
by and between Therapix Biosciences Ltd., a company organized under the laws of the State of Israel (the "Company")
with registered address at Azrieli Center, 27th floor, Tel-Aviv 67025, Israel, and Doron Ben-Ami ,ID no. 57690653 (the
"Consultant"). The Company and the Consultant shall sometimes be referred to, each as a "Party"
and collectively, as the "Parties".

 

	WHEREAS,	the Company desires to engage the Consultant as its
Chief Strategy Officer and the Consultant desires to serve the Company in such position, on the terms and conditions hereinafter
set forth.

 

NOW,
THEREFORE, based on the representations contained herein and in consideration of the mutual promises and covenants set forth
herein, the Parties agree as follows:

 

	1.	Services

 

		1.1.	Commencing
                                         as of the Effective Date, the Consultant will perform such services and will have such
                                         duties, authorities and responsibilities as are consistent with the position of Chief
                                         Strategy Officer, reporting directly to the CEO. Such services, together with any other
                                         services and tasks assigned to the Consultant from time to time and agreed upon with
                                         the Consultant in advance, shall be referred to herein as the "Services".

 

		1.2.	Consultant
                                         shall devote his attention, know-how, energy, talent, experience and best efforts to
                                         the performance of the Services under this Agreement and the business and affairs of
                                         the Company. Consultant shall be engaged in the position of Chief Strategy Officer on
                                         a part-time basis, such that Consultant shall devote 20% (Twenty percent) of his working
                                         time to the business and affairs of the Company and the performance of his duties and
                                         obligations hereunder.

 

		1.3.	Consultant
                                         shall be available from time to time for consultations by telephone and email, for weekly
                                         teleconferences with the Company and/or meetings with third parties as shall be required
                                         by the Company and coordinated in advance with Consultant.

 

		1.4.	The
                                         Parties agree that Consultant shall be an independent contractor of the Company and in
                                         no event shall an employer-employee or principal-agent relationship be established between
                                         the Company and Consultant. Consultant acknowledges and undertakes that it shall not
                                         represent itself as an agent of the Company, except to the extent expressly authorized
                                         by the Company's Board of Directors (the "Board").

 

		1.5.	The
                                         Parties agree that the execution and delivery of this Agreement and any provision hereof
                                         shall be subject to the approval of the Company's relevant corporate organs and all applicable
                                         laws and regulations, including, without limitation, approvals of the Israeli Securities
                                         Authority and the Tel Aviv Stock Exchange Ltd., (and the OTCQB, if required), and nothing
                                         herein shall be construed deemed a breach of this Agreement in the event that such required
                                         approval is not obtained.

 

    	 		 

     

    

 

	2.	Representations
                                         and Warranties

 

		2.1.	Consultant
                                         hereby represents, warrants and covenants to the Company, and acknowledges that the Company
                                         is entering into this Agreement in reliance thereon, as follows:

 

		2.2.	Consultant
                                         has the necessary skills, knowledge and experience to fulfill Consultant’s obligations
                                         hereunder, shall do so diligently, professionally and conscientiously and shall use Consultant’s
                                         best efforts in the performance thereof.

 

		2.3.	The
                                         execution and delivery of this Agreement and the fulfillment of the terms hereof will
                                         constitute the valid, binding and enforceable obligations of Consultant and will not
                                         violate, conflict with or constitute a default under or breach of any agreement and/or
                                         undertaking and/or instrument, judgment, order, writ or decree to which Consultant is
                                         a party or by which he is bound, or any provision of law, rule or regulation applicable
                                         to Consultant, including without limitation, any confidentiality or non competition agreement,
                                         and do not require the consent of any person or entity. In the performance of Consultant’s
                                         obligations hereunder, Consultant will not make use of (i) any confidential or proprietary
                                         information belonging to any third party, or (ii) any information which Consultant is
                                         restricted from disclosing or using due to contractual undertakings or by law.

 

		2.4.	In
                                         the performance of Consultant’s duties hereunder, Consultant shall comply with
                                         all applicable laws and regulations, including, without limitation, the Company Internal
                                         Compliance Plan (as defined below).

 

		2.5.	Consultant
                                         will refrain from engaging in any business or other activity which may be of conflict
                                         of interest with Consultant’s duties and obligations hereunder, and shall promptly
                                         notify the Company of any such matter or activity.

 

	3.	Compensation
                                         

 

As
full consideration for the Services during the Term on this Agreement (as defined below), the Consultant shall be entitled to
the following:

 

		3.1.	Within
                                         7 days following the end of the first calendar month during which the Services hereunder
                                         are provided, Consultant shall notify the Company of his election to receive a Monthly
                                         Fee or Accrued Fee (as both are defined below). The applicable provisions shall apply
                                         accordingly:

 

		3.1.1.	Monthly
                                         Fee.

 

Commencing
as of the Effective Date, the Company shall pay the Consultant a monthly retainer consulting fee of NIS 8,000 in consideration
for Services, plus V.A.T (the "Monthly Fee").

 

The
Monthly Fee shall be payable within ten (10) days following the end of each calendar month, against the submission at the beginning
of each month to the Company of a valid invoice in relation to the preceding month. A Tax Invoice will be issued following actual
payment transfer of the Monthly Fee, to be wired into an account to be designated by the Consultant and advised in writing to
the Company.

 

    	 	1	 

     

    

 

		3.1.2.	Accrued
                                         Fee. 

 

		a.	In
                                         case the Consultant elects not to receive the Monthly Fee, the Consultant shall be entitled
                                         to an accrued fee equal to the monthly retainer consulting fee of NIS 8,000 in plus VAT,
                                         accumulated during the Term (as such is defined below) (the "Accrued Fee").

 

Unless
converted into equity in accordance with Section 3.1.2(b) below, the Accrued Fee shall be payable within thirty (30) days following
the date of termination or expiration of this Agreement, against the submission by the Consultant to the Company of a valid invoice
in relation to the preceding month. A Tax Invoice will be issued following actual payment transfer of the Accrued Fee, to be wired
into an account to be designated by the Consultant and advised in writing to the Company.

 

		b.	Within
                                         5 (five) days following the termination or expiration of this Agreement, Consultant shall
                                         notify in writing to the Company if he desires to convert the Accrued Fee to Ordinary
                                         Shares of the Company, par value NIS 0.01 (the "Ordinary Shares" and
                                         collectively, the "Conversion"), in lieu of payment of the Accrued Fee.
                                         The Conversion shall be calculated based on the average closing price per Ordinary Share
                                         during the preceding 30 trading days prior to Consultant's election date with respect
                                         to such Conversion. If Consultant shall not notify the Company in the abovementioned
                                         manner, the Company shall elect, in its sole discretion, by which specific method as
                                         described in this sub section to pay the Consultant the Accrued Fee.

 

		c.	The
                                         Conversion shall be subject to the obtainment by the Company of all (i) applicable corporate
                                         approvals, including, without limitation, approvals by the Board and the shareholders
                                         of the Company; and (ii) completion of appropriate filings with and obtainment of the
                                         required approvals of the Israeli Securities Authority and/or the Tel Aviv Stock Exchange
                                         Ltd., (and the OTCQB, if required).

 

In
case Consultant elects the Conversion method, yet a regulatory approval (if indeed shall be required) is not obtained, for reasons
beyond the Company’s control, this shall not be considered to be a breach by the Company of this agreement, Consultant shall
not hold any demand, allegations or claims against the Company, in such event and the Parties shall cooperate in good faith to
achieve any other agreed arrangement they deem suitable in this matter.

 

Nothing
herein shall be construed as an obligation to grant the Consultant of any Ordinary Shares underlying the Conversion.

 

    	 	2	 

     

    

 

		d.	In
                                         the event that any applicable approval according to sub-section c above is not obtained
                                         within 45 (forty five) days following Consultant's notification to the Company of his
                                         election to convert according to sub-section b above, then the Company shall pay the
                                         Consultant the Accrued Fee, and the Conversion shall become null and void.

 

		e.	In
                                         any case, and for demonstrational and regulatory purposes only, such Conversion shall
                                         not entitle the Consultant for more than 1,713,357 Ordinary Shares (which as of November
                                         29, 2015 share trading price demonstrates an accrued fees of NIS 1,559,155 (approximately
                                         155,156 monthly fees), and which shares reflect 4.99% of the issued and outstanding share
                                         capital of the Company as of the Effective Date). Nothing herein shall be construed as
                                         an obligation by the Company to engage with the Consultant for said period (or any part
                                         thereof), and the abovementioned calculations are to be used for demonstrational and
                                         regulatory purposes only, and in any event shall not derogate from the provisions of
                                         section 10 [Term and Termination] to this Agreement.

 

		3.1.3.	Option.
                                         

 

		a.	Subject
                                         to and upon the later of (i) the sole discretion and approval of the Board, the shareholders
                                         of the Company and any applicable Company organs, law or regulation, to the extent applicable
                                         (ii) the Company's Compensation Policy then in effect, (iii) the adoption of an Employee
                                         Share Option Plan (the "Plan") by the Board and its approval by the
                                         Israeli Tax Authorities, and (iv) the execution by Consultant of a standard option agreement
                                         in a form approved by the Board, Consultant shall be granted with an option to purchase
                                         up to 100,000 Ordinary Shares of the Company, par value NIS 0.01, each under the Plan
                                         (the "Shares" and collectively, the “Option”). The
                                         Option shall be subject to the provisions of the Plan and shall vest over a 3 year period,
                                         on a quarterly basis.

 

		b.	The
                                         grant of the Option shall be subject to the obtainment by the Company of all (i) applicable
                                         corporate approvals, including, without limitation, approvals by the Board and the shareholders
                                         of the Company; and (ii) completion of appropriate filings with and obtainment of the
                                         required approvals of the Israeli Securities Authority and/or the Tel Aviv Stock Exchange
                                         (and the OTCQB, if required).

 

		c.	In
                                         case a regulatory approval (if indeed shall be required) is not obtained, for reasons
                                         beyond the Company’s control, this shall not be considered to be a breach by the
                                         Company of this agreement, Consultant shall not hold any demand, allegations or claims
                                         against the Company in connection with the Company's failure to obtain such regulatory
                                         approval.

 

		d.	Nothing
                                         herein shall be construed as an obligation to grant any options to the Consultant.

 

    	 	3	 

     

    

 

		3.2.	Expenses.
                                         Without derogating from the above, the Company shall reimburse the Consultant for all
                                         out-off pocket expenses reasonably required in the performance of the Services by the
                                         Consultant under this Agreement and approved in advance by the Company. Reimbursement
                                         shall be made against delivery by Consultant to the Company of tax receipts or other
                                         appropriate supporting documentation satisfactory to the Company. Such expenses shall
                                         include travel expenses, which shall be made at business class rates, using Company's
                                         travel agent and most favorable rates, and subject to prior written approval.

 

		3.3.	Consultant
                                         shall be solely responsible to pay all taxes, levies, social benefits, insurance payments
                                         and any other payments required by law due in connection with this Agreement, whether
                                         in Israel or abroad, provided, however, that the Company
                                         may withhold all amounts as required by applicable law from payments hereunder or in
                                         connection with this Agreement.

 

		3.4.	Consultant
                                         shall be not entitled to receive any other right, compensation or payment from the Company,
                                         other than as expressly stated in this Section 3.

 

		3.5.	The
                                         Company shall insure Mr. Doron Ben-Ami under the Company's officers’ insurance
                                         policy, in accordance with its terms.

 

	4.	Proprietary
                                         Rights 

 

		4.1.	The
                                         Consultant agrees and declares that any and all products, improvements, derivations,
                                         materials, processes, techniques, know-how and/or proceeds and any and all inventions,
                                         ideas, discoveries, concepts, works of authorship, designs, data results or initiatives
                                         conceived, conducted, developed, reduced to practice, compiled, created, written, authored,
                                         made and/or produced by the Consultant, alone or jointly with others, pursuant to, in
                                         connection with, resulting or arising from this Agreement and/or the provision of the
                                         Services to the Company, or trade secrets of the Company, whether within the scope of
                                         the provision of the Services hereunder to the Company or otherwise and whether during
                                         the Term of this Agreement, prior thereto or thereafter, directly or indirectly related
                                         to the technology of the Company as currently conducted and/or proposed to be conducted
                                         (the "Inventions") and any and all right, title and interest in and
                                         to the Inventions, including without limitation, all patents, copyrights, trademarks,
                                         trade names, moral rights and other intellectual, industrial and/or proprietary rights
                                         and applications, extensions and renewals thereof (together with the Inventions, the
                                         "Proprietary Rights"), shall be the sole and exclusive property of the
                                         Company, its successors and assigns (for the purpose of this Section 4, collectively,
                                         the "Company"), and that the Consultant will not have any rights or
                                         title whatsoever thereto, including, although not an employee, any right to receive compensation
                                         pursuant to Section 134 of the Israeli Patent Law - 1967. All works authored by the Consultant
                                         pursuant to this Agreement, including, without limitation, the Inventions, shall be deemed
                                         "works made for hire".

 

    	 	4	 

     

    

 

		4.2.	If
                                         and to the extent the Company’s sole and exclusive ownership of the Proprietary
                                         Rights, in whole or in part, is not recognizable for any reason whatsoever, the Consultant
                                         hereby irrevocably transfers and assigns to the Company, solely and exclusively, all
                                         its/his rights, title and interest now and hereafter acquired in and to all Proprietary
                                         Rights (without any payments, liabilities or restrictions to any person or third party)
                                         in any and all media now known or hereafter devised, and all claims and causes of action
                                         of any kind with respect to any of the foregoing, throughout the world in perpetuity,
                                         and, when not otherwise assignable herein, agrees and undertakes to assign in the future
                                         to the Company all right, title and interest in and to any and all such Proprietary Rights
                                         (and all proprietary rights with respect thereto) and further undertakes to execute all
                                         necessary documentation and take all further action as may be required in order to perform
                                         such assignment, at the Company’s expense.

 

		4.3.	In
                                         the event that pursuant to any applicable law the Consultant retains any rights in and
                                         to the Proprietary Rights that cannot be assigned to the Company, the Consultant hereby
                                         unconditionally and irrevocably waives the enforcement of all such rights, and all claims
                                         and causes of action of any kind with respect to any of the foregoing and agrees, at
                                         the request and expense of the Company, to consent to and join in any action to enforce
                                         such rights and to procure a waiver of such rights from the holders of such rights, if
                                         any.

 

		4.4.	In
                                         the event that the Consultant retains any rights in and to Proprietary Rights that cannot
                                         be assigned to the Company and cannot be waived, the Consultant hereby grants the Company
                                         an exclusive, perpetual, worldwide, royalty-free license to exploit, use, develop, perform,
                                         modify, change, reproduce, publish and distribute, with the right to sublicense and assign
                                         such rights, and all claims and causes of action of any kind with respect to any of the
                                         foregoing, in and to the Proprietary Rights, in any way the Company sees fit and for
                                         any purpose whatsoever. Without derogating from the above, the Consultant hereby forever
                                         waives and agrees never to assert any and all rights of paternity or integrity, any right
                                         to claim authorship of any Invention, to object to any distortion, mutilation or other
                                         modification of, or other derogatory action in relation to any Invention, whether or
                                         not such would be prejudicial to his honor or reputation, and any similar right, existing
                                         under judicial or statutory law of any country in the world, or under any treaty, even
                                         after termination of its/his work on behalf of the Company.

 

		4.5.	Without
                                         derogating from the above, any and all material (including, without limitation, software,
                                         designs, documentation, memoranda, notes, reports, manuals, patterns, programs, specifications,
                                         prototypes, formulas, drawings, records, data or other technical or proprietary information),
                                         and any copies or abstracts thereof, whether or not of a secret or confidential nature,
                                         furnished to the Consultant by the Company or conceived, conducted, developed, reduced
                                         to practice, compiled, created, written, authored, made and/or produced by the Consultant,
                                         alone or jointly with others, pursuant to, in connection with, resulting or arising from
                                         this Agreement and/or the provision of Services to the Company, or trade secrets of the
                                         Company, whether within the scope of the consultancy with the Company or otherwise and
                                         whether during the Term of this Agreement, prior thereto or thereafter, directly or indirectly
                                         related to the business of the Company as currently conducted and/or proposed to be conducted,
                                         is and shall remain the sole and exclusive property of the Company. Such property while
                                         in the Consultant’s custody or control, as applicable, shall be maintained in good
                                         condition at Consultant’s expense, as applicable.

 

    	 	5	 

     

    

 

		4.6.	The
                                         Consultant will promptly disclose to the Company fully and in writing (but otherwise
                                         keep in confidence) all Inventions. All inventions and proprietary rights owned by the
                                         Consultant prior to the Effective Date are set forth in Exhibit A hereto,
                                         and shall remain the sole and exclusive property of the Consultant. Consultant hereby
                                         agrees and undertakes to provide the Company or any person designated by the Company
                                         all such information, to execute all necessary documentation and to take all further
                                         action as may be required to perfect the rights referred to herein, including, without
                                         limitation, any assignment of rights to the Company or the obtaining or enforcing any
                                         intellectual property rights, if applicable, in any and all countries, provided, that
                                         the Company will compensate the Consultant at a reasonable rate for time or expenses
                                         actually spent by him at the Company’s request on such assistance. Without derogating
                                         from any of the Consultant’s obligations hereunder, the Consultant hereby appoints
                                         any officer of the Company as its duly authorized agent to execute, file, prosecute and
                                         protect the same before any government agency, court or authority.

 

		4.7.	Consultant’s
                                         undertakings in this Section ‎4 shall remain in full force and effect after termination
                                         or expiration of this Agreement for any reason whatsoever or any renewal thereof.

 

	5.	Confidentiality
                                         

 

		5.1.	Consultant
                                         represents and warrants that it will keep the terms and conditions of this Agreement
                                         strictly confidential and will not disclose it or provide a copy of this Agreement or
                                         any part thereof to any third person unless and to the extent required by applicable
                                         law and except for his counsels Advisors and first degree family member, and only on
                                         a need to know basis.

 

		5.2.	Any
                                         and all information and data of a proprietary or confidential nature concerning the business
                                         or financial activities of the Company or its technology or products (whether current
                                         or future), whether in oral, written, graphic, machine-readable form, or in any other
                                         form, including, without limitation, proprietary, business, financial, technical, development,
                                         product, marketing, sales, price, operating, performance, cost, know-how and process
                                         information, trade secrets, patents, patent applications, copyrights, ideas and inventions
                                         (whether patentable or not), and all record bearing media containing or disclosing such
                                         information and techniques, disclosed to or otherwise acquired by the Consultant in connection
                                         with this Agreement and any and all Proprietary Rights (collectively, "Confidential
                                         Information") is and shall remain the sole and exclusive property of the Company.

 

		5.3.	At
                                         all times, both during the term of this Agreement and thereafter, the Consultant: (i)
                                         will keep the Confidential Information strictly confidential and will not disclose it,
                                         or any part thereof, provide any documentation with respect thereto, or any part thereof,
                                         directly or indirectly, to any third party, without the prior written consent of the
                                         Company or unless and to the extent required by applicable law; and (ii) will not use
                                         any Confidential Information or anything relating to it without the prior written consent
                                         of the Company, except and to the extent as may be necessary in the ordinary course of
                                         performing its/his duties and obligations hereunder and in the best interests of the
                                         Company. Notwithstanding the foregoing, the Consultant shall not be obligated to maintain
                                         the confidentiality of the Confidential Information which: (i) is or becomes a matter
                                         of public knowledge through no fault of the Consultant, or breach of this Agreement;
                                         (ii) is authorized, in writing, by the Company for release; (iii) was lawfully in the
                                         Consultant’s possession before receipt from the Company, as evidenced by the Consultant,
                                         as the case may be, through written documentation; (iv) is lawfully received by the Consultant
                                         from a third party without a duty of confidentiality; or (v) reflects information and
                                         data generally known within the industries or trades in which the Company transacts business
                                         or (vi) is required to be revealed by a competent authority's decision.

 

    	 	6	 

     

    

 

		5.4.	At
                                         all times, both during the term of this Agreement and thereafter Consultant will keep
                                         in trust all Confidential Information. In the event of the termination of this Agreement
                                         for any reason, or upon the Company’s earlier request, the each of the Consultant
                                         will promptly deliver to the Company all materials referred to herein and the Consultant
                                         shall not retain or take any materials, or any reproduction thereof containing or pertaining
                                         to Confidential Information.

 

		5.5.	The
                                         Consultant recognizes that the Company received and will receive confidential or proprietary
                                         information from third parties, subject to a duty on the Company’s part to maintain
                                         the confidentiality of such information and to use it only for certain limited purposes.
                                         At all times, both during the Term of this Agreement and after its termination, the Consultant
                                         undertakes to keep any and all such information in strict confidence and trust, and it
                                         will not use or disclose any of such information without the prior written consent of
                                         the Company, except as may be necessary to perform his duties hereunder and consistent
                                         with the Company’s agreement with such third party. Upon termination of this Agreement,
                                         the Consultant shall act with respect to such information as set forth in Section 5.4.

 

	6.	Indemnification

 

		6.1.	The
                                         Consultant is an independent contractor and it and its employees and consultants do not
                                         and shall not represent themselves to be the agents, employees, partners or joint venturers
                                         of the Company. Nothing in this Agreement shall be interpreted or construed as creating
                                         or establishing any partnership, joint venture, employment relationship, franchise or
                                         agency or any other similar relationship between the Company and the Consultant or any
                                         of its employees and consultants and neither party shall be held liable for the debts
                                         or obligations of the other.

 

		6.2.	The
                                         Consultant hereby undertakes to indemnify and reimburse the Company for any amounts claimed
                                         or levied on the Company (including related costs and expenses) due to taxes, social
                                         insurance payments, pension payments, health insurance and any other such payments resulting
                                         from any payment made by the Company to the Consultant under this Agreement, whether
                                         in connection to Consultant.

 

		6.3.	Without
                                         derogating from the above, in the event that, notwithstanding the Parties’ representations
                                         and undertakings hereunder, the Consultant or anyone on its behalf, shall claim, or a
                                         court of competent jurisdiction shall determine, the existence of employer-employee relationship
                                         between the Consultant and the Company, then the following provisions shall apply: (i)
                                         the Consultant's monthly salary for such claimed or determined period of employer-employee
                                         relationship shall be equal to 70% (seventy percent) of the sum of the Monthly Fee and
                                         expenses reimbursement due to the Consultant as consideration for the Services rendered
                                         hereunder (for the purposes of this Section ‎6.3, the "Monthly Salary");
                                         and (ii) the Monthly Salary shall be deemed to constitute all of the Company’s
                                         liabilities and obligations towards the Consultant, of any source or origin, with respect
                                         to and in connection with said employer-employee relationship, except for such rights
                                         with respect to which global compensation may not be determined pursuant to applicable
                                         law. The Company shall be entitled to set-off any amount due to it pursuant to this Section
                                         ‎6.3 from any amount due to Consultant pursuant to this Agreement.

 

    	 	7	 

     

    

 

	7.	Non
                                         Competition; Non Solicitation

 

		7.1.	Consultant,
                                         agrees and undertakes that he will not, during the Term of this Agreement and for a period
                                         of one (1) year thereafter, compete or assist others to compete, whether directly or
                                         indirectly, with the business of the Company, as currently conducted and/or proposed
                                         to be conducted.

 

		7.2.	Consultant
                                         agrees and undertakes that during the Term of this Agreement and for a period of one
                                         (1) year thereafter, it/she will neither solicit for employment or any other engagement
                                         nor employ or otherwise engage any person employed by the Company on the date of such
                                         termination or during the preceding twelve (12) months, personally or in any business
                                         in which he is an officer or director, for any purpose or in any place, provided that
                                         the foregoing restriction shall not apply to employment or engagement of an employee:
                                         (i) following an employee’s affirmative response to a general recruitment effort
                                         carried out through a public solicitation or general solicitation, or (ii) upon an employee’s
                                         initiative.

 

		7.3.	If
                                         any one or more of the terms contained in Sections ‎7.1 and ‎7.2 shall, for any
                                         reason, be held to be excessively broad with regard to time, geographic scope or activity,
                                         such term shall be construed in a manner to enable it to be enforced to the extent compatible
                                         with applicable law.

 

	8.	Compensation
                                         Policy

 

		8.1.	Consultant
                                         declares and confirms, that he is familiar and aware that the Company has adopted a compensation
                                         policy pursuant to the provisions of the Companies Law 5759-1999 (the "Compensation
                                         Policy", and the "Law", respectively), and that the terms of
                                         this Agreement are subject to and shall be aligned with the provisions and guidelines
                                         of the Compensation Policy in force, and as shall be determined from time to time. Copy
                                         of the Compensation Policy is attached hereto as an integral part of this Agreement.

 

		8.2.	In
                                         the event that this Agreement and/or any of its provisions shall be proclaimed and/or
                                         considered by a competent authority not aligned with the Compensation Policy and not
                                         in accordance with the provision of the Law ("Contradicting Term"),
                                         then the Parties shall cooperate to adjust any Contradicting Term with the Compensation
                                         Policy or to be approved by the Company’s relevant organs, as per the Parties consent
                                         and in accordance with applicable law and regulations.

 

		8.3.	Without
                                         derogating from the Consultant’s rights under this Agreement, in the event that
                                         the abovementioned adjustment is not possible or achievable under the circumstances,
                                         Consultant shall not hold any demand, allegations or claims against the Company, in the
                                         event the Company cannot make the necessary adjustment for reasons beyond the Company’s
                                         control.

 

		8.4.	Without
                                         derogating from the provisions of the Compensation Policy, to the extent that any amount
                                         or fees paid to the Consultant hereunder shall be revealed, within three (3) years of
                                         the payment thereof, to have been paid based on erroneous calculations that have been
                                         restated in the Company's financial statements, the Consultant shall repay the Company
                                         amount paid in excess as aforesaid; all in accordance with the provisions of the Compensation
                                         Policy.

 

    	 	8	 

     

    

 

	9.	Securities
                                         Internal Compliance Plan; Insider Trading Policy

 

Consultant
declares and confirms, that he is familiar and aware that the Company has adopted a Securities Internal Compliance Plan (the "Internal
Compliance Plan"), and are familiar with its terms, obligations and restrictions, and shall act in accordance with the
provisions and guidelines of the Internal Compliance Plan in force, and as shall be determined from time to time.

 

	10.	Term
                                         and Termination

 

		10.1.	This
                                         Agreement shall be in effect as of the Effective Date and shall continue in full force
                                         and effect for an undefined period, until terminated as hereinafter provided (the "Term").

 

		10.2.	At
                                         any time commencing as of the Effective Date, each party shall have the right to terminate
                                         this Agreement, with or without cause, by providing a 30-day advance written notice to
                                         the other party (the " Notice Period"), during which Consultant shall
                                         be obligated to continue to provide the Services to the Company, unless instructed otherwise
                                         by the Company and in such event he shall be entitled to the compensation due to him
                                         until the original end date. During the Notice Period, the Consultant shall be entitled
                                         to all Compensations detailed in Section ‎3 above, to the extent applicable.

 

Upon
such time that Consultant ceases to provide the Services hereunder, it shall immediately return to Company any and all equipment
provided to the Consultant pursuant to this Agreement, if any.

 

		10.3.	Notwithstanding
                                         anything to the contrary herein, the Company may terminate this Agreement at any time,
                                         effective immediately, without need for prior written notice, and without derogating
                                         from any other remedy to which the Company may be entitled, for Cause. For the purposes
                                         of this Agreement, the term "Cause" shall mean, but shall not be limited
                                         to: (i) a material breach by Consultant of any term of this Agreement; (ii) any breach
                                         by Consultant of its fiduciary duties to the Company, including, without limitation,
                                         any material conflict of interest for the promotion of Consultant’s benefit; (iii)
                                         Consultant fraud, felonious conduct or dishonesty; (iv) Consultant’s embezzlement
                                         of funds of the Company; (v) any conduct by Consultant which is materially injurious
                                         to the Company, monetary or otherwise; (vi) Consultant’s conviction of any felony;
                                         (vii) Consultant’s misconduct, gross negligence or willful misconduct in performance
                                         of his duties and/or responsibilities hereunder; or (viii) Consultant’s refusal
                                         to perform its duties and/or responsibilities hereunder for any reason other than illness
                                         or incapacity of Consultant, or Consultant’s disregard or insubordination of any
                                         lawful resolution and/or instruction of the Board with respect to Consultant’s
                                         duties and/or responsibilities towards the Company.

 

		10.4.	Upon
                                         termination of this Agreement, the Consultant shall cooperate with the Company and use
                                         its best efforts to assist the integration into the Company’s organization of the
                                         person or persons who will assume the Consultant’s responsibilities. At the option
                                         of the Company, the Consultant shall, during such period, either continue with its duties
                                         or remain absent from the premises of the Company, subject to applicable law.

 

    	 	9	 

     

    

 

	11.	Survival

 

The
provisions of Sections 3.3, ‎4 through 8 and ‎13.5 shall survive the termination of this Agreement for any reason whatsoever.

 

	12.	Notices
                                         

 

		12.1.	Any
                                         and all notices and communications in connection with this Agreement shall be in writing,
                                         addressed to the parties as follows:

 

	 	If
    to the Company:	Therapix
        Biosciences Ltd.

        

        Azrieli
        Center, 27th floor,

        Tel-Aviv
67025, Israel

	 	 	 
	 	If
    to Consultant:	

        

         

	 	 	 

		12.2.	All
                                         notices shall be given by registered mail (postage prepaid), by facsimile or email or
                                         otherwise delivered by hand or by messenger to the Parties’ respective addresses
                                         as above or such other address as may be designated by notice. Any notice sent in accordance
                                         with this Section ‎12 shall be deemed received upon the earlier of: (i) if sent by
                                         facsimile or email, upon transmission and electronic or other confirmation of receipt
                                         or (if transmitted and received on a non-business day) on the first business day following
                                         transmission and electronic or other confirmation of receipt, (ii) if sent by registered
                                         mail, upon 5 (five) days of mailing, and (iii) if sent by messenger, upon delivery.

 

	13.	Miscellaneous.

 

		13.1.	The
                                         execution, delivery and performance of this Agreement is subject to the obtainment of
                                         all applicable corporate and regulatory approvals, if and to the extent necessary.

 

		13.2.	Headings;
                                         Interpretation. Section headings contained herein are for reference and convenience
                                         purposes only and shall not in any way be used for the interpretation of this Agreement.

 

		13.3.	Entire
                                         Agreement. This Agreement constitutes the entire agreement between the Parties with
                                         respect to the subject matters hereof and supersedes all prior agreements, understandings
                                         and arrangements, oral or written, between the Parties with respect to the subject matters
                                         hereof.

 

		13.4.	Amendment;
                                         Waiver. No provision of this Agreement may be modified, waived or discharged unless
                                         such waiver, modification or discharge is agreed to in writing and signed by all Parties.
                                         No waiver by either Party at any time to act with respect to any breach or default by
                                         the other Party of, or compliance with, any condition or provision of this Agreement
                                         to be performed by such other Party shall be deemed a waiver of similar or dissimilar
                                         provisions or conditions at the same or at any prior or subsequent time.

 

    	 	10	 

     

    

 

		13.5.	Governing
                                         Law; Jurisdiction. This Agreement shall be governed by and construed and enforced
                                         in accordance with the laws of the State of Israel, without giving effect to the rules
                                         with respect to conflicts-of-law. Any dispute arising out of, or relating to this Agreement,
                                         its interpretation or performance hereunder shall be resolved exclusively by the competent
                                         court of the Central district, and each of the Parties hereby submits exclusively and
                                         irrevocably to the jurisdiction of such court.

 

		13.6.	Severability.
                                         The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability
                                         of any provision shall not affect the validity or enforceability of the other provisions
                                         hereof. If any part of this Agreement is determined to be invalid, illegal or unenforceable,
                                         such determined shall not affect the validity, legality or enforceability of any other
                                         part of this Agreement; and the remaining parts shall be enforced as if such invalid,
                                         illegal, or unenforceable part were not contained herein, provided, however,
                                         that in such event this Agreement shall be interpreted so as to give effect, to the greatest
                                         extent consistent with and permitted by applicable law, to the meaning and intention
                                         of the excluded provision as determined by such court of competent jurisdiction.

 

		13.7.	Successors
                                         and Assign; Assignment. This Agreement shall be binding upon and shall inure to the
                                         benefit of the Company, its successors and assigns. Neither this Agreement or any of
                                         the Consultant’s rights, privileges, or obligations set forth in, arising under,
                                         or created by this Agreement may be assigned or transferred by the Consultant without
                                         the prior consent in writing of the Company, except by will or by the laws of descent
                                         and distribution

 

[the
remainder of this PAGE was intentionally left blank]

 

    	 	11	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Consulting Agreement as of the date first above-mentioned.

 

     

	/s/ Elran Haber	 	/s/ Doron Ben - Ami
	Therapix
Biosciences Ltd. 	 	Doron
Ben-Ami

 

	By:	Elran Haber 	 	 
	Title:	CEOExhibit 10.9

Execution
Copy

 

Financial
Services Agreement

  

This
agreement (the “Agreement”) is entered into as of this __ day of November 2015 (the "Effective Date")
between Therapix Biosciences Ltd. with principal offices at 5 Azrieli Center, 27th floor, Tel-Aviv 67025, Israel and its subsidiaries
(the "Company") and Mr. Guy Goldin, licensed CPA, ID no. 029410768, of Klauzner 3th St. Ramat-Gan
(“Contractor”).

 

	Whereas	the
    Company is a public company whose securities are traded on the Tel-Aviv Stock Exchange; and

 

	Whereas	Contractor
    is engaged with Baseline, Licensed Dealer no. _______ and renders certain financial services to companies as a consultant;

 

	Whereas	the
    Company wishes to retain services from the Contractor and the Contractor wishes to render such services to the Company, as
    further set forth herein; and

 

	Whereas	the
    Contractor represents that it has the required knowledge, ability, talent and experience to provide services to the Company,
    all as detailed and pursuant to the terms set forth herein.

 

Now,
therefore, the parties have agreed as follows:

 

	1.	Services

 

	 	1.1	The
    Contractor will provide the Company with a finance director services as customary to be provided by an office holder holding
    such position in a publicly traded company, including financial services, as an independent contractor, which, , will include
    inter alia the services set forth in Exhibit A hereto (the “Services”).

 

	 	1.2	The
    Services shall be provided by Mr. Guy Goldin personally.

 

	 	1.3	The
    Contractor shall report directly to the Company's CEO.

 

	 	1.4	The
    scope of the Services shall be determined by the Company's CEO from time to time, according to the Company’s needs.

 

	 	1.5	The
    Contractor shall immediately notify the Company's CEO regarding any matter it has and/or may have a personal interest in which
    may affect the rendering of the Services.

 

	 	1.6	The
    Contractor shall perform the Services diligently and promptly for the sole benefit of the Company. The Contractor shall competently
    perform all assigned duties, carry out the policies, directives and decisions of the CEO of the Company; not withhold information
    from the Company and refrain from any conduct which is illegal, dishonest, fraudulent or detrimental to the Company's business.

 

	 	1.7	Contractor
    shall devote his attention, know-how, energy, talent, experience and best efforts to the performance of the Services under
    this Agreement and the business and affairs of the Company. Contractor shall be engaged with the Company on a part-time basis,
    such that Contractor shall devote up approximately 70 hours per month for the ongoing work and additional up to 35 hours per
    quarter for the performance of the Services, as shall be instructed by the Company. In the event that the parties will see
    a need to increase the scope of work, the parties shall negotiate and mutually agree – if possible - on an updated fee.

 

     

     

    

 

	2.	Representations
    and Warranties

 

	 	2.1	Contractor
    hereby represents, warrants and covenants to the Company, and acknowledges that the Company is entering into this Agreement
    in reliance thereon, as follows:

 

	 	2.2	Contractor
    has the necessary skills, knowledge and experience to fulfill Contractor’s obligations hereunder, shall do so diligently,
    professionally and conscientiously and shall use Contractor’s best efforts in the performance thereof.

 

	 	2.3	The
    execution and delivery of this Agreement and the fulfillment of the terms hereof will constitute the valid, binding and enforceable
    obligations of Contractor and will not violate, conflict with or constitute a default under or breach of any agreement and/or
    undertaking and/or instrument, judgment, order, writ or decree to which Contractor is a party or by which he is bound, or
    any provision of law, rule or regulation applicable to Contractor, including without limitation, any confidentiality or non
    competition agreement, and do not require the consent of any person or entity. In the performance of Contractor’s obligations
    hereunder, Contractor will not make use of (i) any confidential or proprietary information belonging to any third party, or
    (ii) any information which Contractor is restricted from disclosing or using due to contractual undertakings or by law. Contractor
    hereby represents and warrants that he has obtained all approvals necessary by third parties with respect to his the execution,
    delivery and performance of this Agreement.

 

	 	2.4	In
    the performance of Contractor’s duties hereunder, Contractor shall comply with all applicable laws and regulations,
    including, inter alia, the Company Internal Compliance Plan (as defined below).

 

	 	2.5	Contractor
    will refrain from engaging in any business or other activity which may be of conflict of interest with Contractor’s
    duties and obligations hereunder, and shall promptly notify the Company of any such matter or activity.

 

	3.	Term

 

	 	3.1	This
    Agreement shall commence on the date hereof and shall remain in full force and effect (the “Term”) unless
    terminated, for any reason, with a thirty (30) days prior written notice (the "Notice Period").

 

	 	3.2	During
    the Notice Period the Contractor shall continue providing the Services and be entitled to the Monthly Fees (as defined below).
    Nevertheless, the Company may, under its sole discretion, waive retaining the Services during the Notice Period, in whole
    or in part, subject to paying the Contractor the Monthly Fees, had it continued providing the Services until the end of the
    Notice Period.

 

	 	3.3	Notwithstanding
    the above, the Company may terminate this Agreement with immediate effect, without providing any notice upon the occurrence
    of any of the following: (a) The Contractor has breached any of its confidentiality obligations towards the Company, (b) the
    prosecution of the Contractor for any felony whatsoever, and (c) a violation by the Contractor of its fiduciary duties towards
    the Company.

 

	 	3.4	Upon
    any the termination of this Agreement and subject to paying the applicable Monthly Fees and final account to the Contractor,
    Contractor shall immediately provide the Company all written, electronic and other records of Company in its possession, in
    a form reasonably requested by Company. During the Notice Period, Contractor shall provide all necessary consultations, hand-off
    and instructions services to any replacement of Contractor hired by Company.

 

	4.	Consideration

 

	 	4.1	As
    full and complete consideration for the Services, the Company shall pay to Contractor monthly fees for the Services in an
    amount of NIS 19,000 plus VAT for each month (the “Monthly Fees”).

 

	 	4.2	The
    Monthly Fees will be paid at within 10 days of the end of each calendar month as a wire transfer, against a proper tax invoice
    of The Contractor.

 

    2

     

    

 

	 	4.3	The
    Company shall reimburse Contractor for expenses incurred in connection with the fulfillment of his duties hereunder, in an
    amount of NIS 1,000 + VAT per month against tax invoice provided by the contractor. Reimbursement shall be made upon payment
    of the Monthly Fees.

 

	 	4.4	In
    addition to clause 4.3 Company shall reimburse the Contractor for all out-off pocket expenses reasonably required in the performance
    of the Services by the Contractor under this Agreement and approved in advance by the Company. Reimbursement shall be made
    against delivery by Contractor to the Company of tax receipts or other appropriate supporting documentation satisfactory to
    the Company.

 

	 	4.5	Option.
    

 

	 	4.5.1.	Subject
    to and upon the later of (i) the sole discretion and approval of the Company's Board of Directors (the "Board"),
    the shareholders of the Company and any applicable Company organs, law or regulation, to the extent applicable (ii) the Company's
    Compensation Policy then in effect, (iii) the adoption of an Employee Share Option Plan (the "Plan") by the
    Board and its approval by the Israeli Tax Authorities, and (iv) the execution by Contractor of a standard option agreement
    in a form approved by the Board, Contractor shall be granted with an option to purchase up to 200,000 Ordinary Shares of the
    Company, par value NIS 0.1, each under the Plan (the "Shares" and collectively, the “Option”).
    The Option shall be subject to the provisions of the Plan and shall vest over a 3 year period, on a quarterly basis. The Option
    shall be exercisable in linear stages as set forth above provided that Mr. Goldin shall be continuously engaged by the Company.
    To the extent the Services were terminated prior to an end of a quarter, Contractor shall be entitled to the respective pro-rata
    portion of the Option.

 

	 	4.5.2.	Subject
    any applicable laws or regulations, the term of the Option and the exercise price of each Share underlying the Option shall
    be determined by the Board, at its sole discretion.

 

	 	4.5.3.	The
    grant of the Option shall be subject to the obtainment by the Company of all (i) applicable corporate approvals, including,
    without limitation, approvals by the Board and the shareholders of the Company; and (ii) completion of appropriate filings
    with and obtainment of the required approvals of the Israeli Securities Authority and/or the Tel Aviv Stock Exchange (and
    the OTCQB, if required).

 

	 	4.5.4.	In
    case a regulatory approval (if indeed shall be required) is not obtained, for reasons beyond the Company’s control,
    this shall not be considered to be a breach by the Company of this agreement, Contractor shall not hold any demand, allegations
    or claims against the Company in connection with the Company's failure to obtain such regulatory approval.

 

	 	4.5.5.	Nothing
    herein shall be construed as an obligation to grant any options to the Contractor.

 

	 	4.6	Contractor
    shall be solely responsible and shall make all compulsory payments in connection with the Services provided hereunder. Said
    payments shall include, without limitation, income tax, National Insurance, severance, and any and all other payments to any
    governmental or other relevant authority in connection with the Services.

 

	 	4.7	Contractor
    shall be solely responsible for any tax and other payments required by law in connection with this Agreement and the payment
    or remittance of any portion of the Consulting Fee hereunder, provided, however, that the Company may withhold any amounts
    as required by applicable law from any payments or other forms of compensation hereunder or in connection with this Agreement.

 

    3

     

    

 

	 	4.8	The
    Contractor shall not be entitled to receive any other compensation or payment from the Company other than as expressly stated
    in this section 4.

 

	5. 	Insurance;
    Indemnification and Exemption

 

	 	5.1	The
    Company shall insure Mr. Guy Goldin under the Company's officers’ insurance policy, in accordance with its terms.

 

	 	5.2	Subject
    to the obtainment of all corporate and regulatory approvals, to the extent required, Contractor shall be entitled to exemption
    and indemnification in connection with the performance of the Services hereunder, in accordance with the Exemption and Indemnification
    Letters in the forms previously approved by the Board.

 

	6. 	Confidentiality,
    Proprietary Rights & Non-Competition 

 

A
Confidentiality, Proprietary Rights and Non-Competition agreement between the parties is attached as Exhibit B hereto
and forms an integral part of this Agreement.

 

	7.  	Independent
    Contractor

 

	 	7.1	The
    parties agree that Contractor shall act as an independent contractor in the performance of the Services and that nothing contained
    herein shall create or be construed to create an employer-employee relationship between the parties and Contractor shall not
    be entitled to any Company employment rights or benefits.

 

	 	7.2	Without
    derogating from the above, in the event that, notwithstanding the parties’ representations and undertakings hereunder,
    the Contractor, or anyone on its behalf, shall claim, or a court of competent jurisdiction shall determine, the existence
    of employer-employee relationship between the Contractor and the Company, then the following provisions shall apply: (i) the
    Contractor's monthly salary for such claimed or determined period of employer-employee relationship shall be equal to 60%
    (sixty percent) of the sum of the Monthly Fees and expenses reimbursement due to the Contractor as consideration for the Services
    hereunder (for the purposes of this Section ‎7, the “Monthly Salary”); (ii) the Monthly Salary shall
    be deemed to constitute all of the Company’s liabilities and obligations towards the Contractor, of any source or origin,
    with respect to and in connection with said employer-employee relationship, except for such rights with respect to which global
    compensation may not be determined pursuant to applicable law, (iii) Contractor will immediately pay the Company all amounts
    paid to it beyond the sums calculated as stated in paragraph (i) above, and (iv) Contractor shall be liable to fully indemnify
    the Company for any damages, liabilities, or other costs and expenses incurred in connection with any such determination.

 

	 	7.3	The
    Company shall be entitled to set-off any amount due to it pursuant to this Section ‎7 from any amount due to Contractor
    pursuant to this Agreement. 

 

	 	7.4	Contractor
    hereby undertakes to indemnify, defend, hold harmless and reimburse the Company, its officers, agents, employees, representatives,
    successors and assigns against any claim, liability, loss and expense, including reasonable attorneys fees, arising from any
    suit, cause of action, demand or claim brought by any person or entity (including related costs and expenses) due to taxes,
    payment or withholding, wages, premiums, contributions social security payments, pension payments, employee benefits, health
    insurance and any other such payments resulting from any payment made by the Company to the Contractor under this Agreement,
    or otherwise in connection herewith.

 

    4

     

    

 

	8. 	Compensation
    Policy

 

	 	8.1	Contractor
    declares and confirms, that it/he is familiar and aware that the Company has adopted a compensation policy pursuant to the
    provisions of the Companies Law 5759-1999 (the "Compensation Policy", and the "Law", respectively),
    and that the terms of this Agreement are subject to and shall be aligned with the provisions and guidelines of the Compensation
    Policy in force, and as shall be determined from time to time.

 

	 	8.2	In
    the event that this Agreement and/or any of its provisions shall be proclaimed and/or considered by a competent authority
    not aligned with the Compensation Policy and not in accordance with the provision of the Law ("Conflicting Provision"),
    then the parties shall cooperate to adjust any Conflicting Provision with the Compensation Policy or to approve such Conflicting
    Provisions by the Company's relevant organs, in accordance with applicable law and regulations.

 

	 	8.3	Without
    derogating from the Contractor’s rights under this Agreement, in the event that the abovementioned adjustment is not
    achievable, the Contractor shall not have any demand, allegations or claims against the Company.

 

	9.	Securities
    Internal Compliance Plan; Insider Trading Policy

 

Contractor
declares and confirms, that he is familiar and aware that the Company has adopted a Securities Internal Compliance Plan (the "Internal
Compliance Plan"), and are familiar with its terms, obligations and restrictions, and shall act in accordance with the
provisions and guidelines of the Internal Compliance Plan in force, and as shall be determined from time to time.

 

	10.	Miscellaneous

 

	 	10.1	During
    the 45 day period commencing on the Effective Date, the Company and Contractor shall negotiate in good faith with respect
    to the appointment of Contractor as the Company's Chief Financial Officer, under the same terms detailed hereunder.

    This Agreement shall be governed by the laws of the State of Israel and the competent courts in Tel-Aviv shall have exclusive
    jurisdiction in all matters pertaining or relating thereto.

 

	 	10.2	This
    Agreement is for the services of the Contractor and none of the Services to be provided by Contractor hereunder may be delegated,
    assigned or subcontracted to others without the prior written consent of the Company, in each case. The Contractor shall not
    be entitled to bind the Company for any purposes unless specifically authorized by the Company in writing in advance.

 

	 	10.3	This
    Agreement constitutes the entire agreement between the parties and supersedes all previous agreements and understandings,
    hereto, whether oral or written, express or implied, with respect to the subject matter contained in this Agreement.

 

	 	10.4	No
    provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed
    to in writing and signed by the Contractor and the Company. No delay or failure by either party hereto at any time to act
    with respect to any breach or default by the other party of, or compliance with, any condition or provision of this Agreement
    to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same
    or at any prior or subsequent time.

 

	 	10.5	All
    notices required to be delivered under this Agreement shall be effective only if in writing and shall be deemed received upon
    the earlier of: (i) if sent by facsimile or email, upon transmission and electronic or other confirmation of receipt or (if
    transmitted and received on a non-business day) on the first business day following transmission and electronic or other confirmation
    of receipt, (ii) five (5) days after the date of mailing if mailed by registered mail to the addresses set forth above; and
    (iii) if sent by messenger, upon delivery.

 

	 	10.6	It
    is agreed between the parties that the Contractor's liability towards the Company shall be that of an office holder under
    the Companies Law-1999 and any other applicable law.

 

	 	10.7	The
    Contractor hereby declares that as of the date hereof it does not hold any securities of the Company, and undertakes to notify
    the Company immediately upon the execution of any transaction whose underlying asset is any of the Company’s securities.

 

	 	10.8	The
    execution, delivery and performance of this Agreement is subject to the obtainment of all applicable corporate and regulatory
    approvals, if and to the extent necessary.

 

[The
remainder of this page was intentionally left blank]

 

    5

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Effective Date.

 

	 /s/
    Elran Haber	 	/s/ Ascher Shmulewitz	 	 /s/
    Mr. Guy Goldin
	Therapix Biosciences Ltd.

	 	The
                    Contractor Mr. Guy Goldin

	 	 	 	 	 	 
	By:	 	 	 	 	By:	 
	 	 	 	 	 	 	 
	Title:	 	 	 	 	Title:	 

 

     

     

    

 

 Annex
A to Services Agreement

The
Services

  

	 	●	Acting
    as the Company's Finance Director ("CFD") and the Company's secretary; 

 

	 	●	Responsible
    for immidiate and periodic reports, including, financial reports and other immidiate, quarterly and annual reports, the Company
    is required to file under applicable law, including in cooperation with the Company’s external accountants as necessary;

 

	 	●	Filing
    immidiate and periodic reports, including, financial reports and other immidiate, quarterly and annual reports, the Company
    is required to file with the public via the "MAGNA system" under applicable law, including the Securities Law-1968
    and the regulations promulgated thereunder after legal review by Company’s legal counsel, so far as such review may
    be required;

 

	 	●	Acting
    as the Compliance Officer of the Company, to the extend nominated by the Company's Audit Committee. 

 

	 	●	Preparing
    board of directors reports and other reports as may be required under applicable law from companies listed on the Tel Aviv
    Stock Exchange and execute such reports in its capacity as the Company's CFD, as required;

 

	 	●	Coordinate
    any future shelf offering report and all related required actions.

 

	 	●	Managing
    on-going bookkeeping & salaries;

 

	 	●	Managing
    the Company's activity with banks and cash flow;

 

	 	●	Participating
    in meetings of the board of directors of the Company and its committees;

 

	 	●	Preparing
    budget control and forecasts;

 

For
the purposes of this Annex A, the term "Company" shall also apply to Company's subsidiaries and affiliates.

 

     

     

    

 

Annex
B to Services Agreement

Confidentiality,
Proprietary Rights and Non-Competition Agreement 

 

The
following Undertaking confirms certain terms of our engagement, jointly and severally, with Therapix Biosciences Ltd. and its
subsidiaries (the "Company"), which is a material part of the consideration for my engagement by the Company
and the compensation received by us from the Company from time to time. Capitalized terms used and not otherwise defined herein
shall bear the respective meanings ascribed to them in the Financial Services Agreement to which this Undertaking is attached
(the "Agreement").

 

	1.	Confidentiality
    

 

	1.1.	I
    acknowledge that in the course of my engagement with the Company I may (or may have) receive(d), learn(ed), be(en) exposed
    to, obtain(ed), or have (had) access to non-public information relating to the Company, its business, operations and activities,
    including without limitation any commercial, financial, business or technical information, inventions, developments, processes,
    specifications, technology, know-how and trade secrets, information regarding marketing, operations, plans, activities, customers,
    suppliers, business partners, etc. ("Confidential Information"), and hereby undertake: (a) to
    maintain the Confidential Information in strict confidence at all times and not to communicate, publish, reveal, describe,
    allow access to, divulge or otherwise disclose, expose or make available the Confidential Information in whole or in part,
    to any person or entity, all whether directly or indirectly, and whether in writing or otherwise; and (b) not
    to use the Confidential Information for any purpose other than for the performance of my obligations pursuant to the Agreement.

 

I
further recognize that (i) the Company may receive confidential or proprietary information from third parties, subject to a duty
on the Company's part to maintain the confidentiality of such information and to use it only for certain limited purposes. Such
information shall also be deemed "Confidential Information" hereunder, mutatis mutandis; and (ii) the Company is a public
company traded on the Tel-Aviv Stock Exchange, and accordingly, Confidential Information may be considered as "inside information"
pursuant to Israeli securities laws and regulations.

 

	1.2.	Notwithstanding,
    Confidential Information shall not include information that: (i) is now or subsequently becomes generally available in the
    public domain through no fault or breach on my part of any of my obligations hereunder and/or under the Agreement (it being
    agreed and understood that Confidential Information shall not be deemed to be in the public domain merely because any part
    of the Confidential Information is embodied in general disclosure or because individual features, components or combinations
    thereof are now or become known to the public); (ii) was either rightfully obtained by the undersigned prior to the date hereof
    from a third party who has the right to transfer or disclose it, or, as the undersigned can demonstrate in its records, was
    rightfully in undersigned’s possession prior to the date hereof, all without duty of nondisclosure or nonuse; (iii)
    is approved in writing by the company for release by the undersigned; or (iv) is required or compelled by law to be disclosed,
    provided that the undersigned gives reasonable prior written notice to the Company in order to allow it to seek protective
    or other court orders. In addition, I represent and warrant that I will keep the terms and conditions of the Agreement and
    this Undertaking strictly confidential and will not disclose it to any third person unless and to the extent required by applicable
    law and subject to prior written notice to the Company. I nevertheless understand and agree that the Company may disclose
    the terms and conditions of the Agreement and this Undertaking if it so deems necessary and that it is particularity required
    to make certain public disclosures and publications under applicable laws which may include the terms and conditions of the
    Agreement and this Undertaking.

 

	1.3.	Upon
    the earlier of the Company's request or the termination of my engagement, I shall return to the Company any and all documents
    and other tangible materials containing Confidential Information, and shall erase or destroy any computer or data files in
    my possession containing Confidential Information, such that no copies or samples of Confidential Information shall remain
    with me.

 

     

     

    

 

	1.4.	Without
    derogating from the above, all Confidential Information made available to, received by, or generated by me shall remain the
    property of the Company (or its respective owners), and no license or other right in or to the Confidential Information is
    granted hereby. Any and all material (including without limitation, files, records, documents, design, drawings, specifications,
    equipment, notebooks, notes, memoranda, diagrams, blueprints, bulletins, formula, reports, analyses, computer programs, software)
    and data of any kind relating to Confidential Information and/or Proprietary Rights (as defined below), whether prepared by
    the undersigned or otherwise coming or having come into my possession, and whether or not marked or classified as Confidential
    Information, shall remain the exclusive property of the Company (or its respective owners).

 

	2.	Proprietary
    Rights

 

	2.1.	Any
    and all right, title and interest in and to any and all discoveries, inventions, ideas, developments, technology, products,
    improvements, enhancements, derivations, modifications, mask works, trade secrets, concepts, ideas, techniques, methods and
    methods of use, delivery and/or diagnostics, processes materials, proceeds, data, compositions of matters, formulations, know-how,
    designs and works of authorship, invented, made, developed, discovered, conceived, conducted, designed, reduced to practice,
    written, authored, compiled, produced and/or created, in whole or in part, by me (or so caused or enabled), independently
    or jointly with others, (i) during my engagement with the Company; or (ii) which result or arise from or relate to my
    engagement with the Company, or work performed by or for the Company, or any Confidential Information; or (iii) with the use
    of any Company equipment, supplies, facilities, trade secrets or proprietary information of the Company; or (iv) which relate
    to the Company's business, technology or research and development (the "Inventions"), and any and all right,
    title and interest in and to the Inventions, including without limitation, all patents, copyrights, trademarks, trade names,
    moral rights and other intellectual, industrial and/or proprietary rights and applications, extensions and renewals associated
    therewith (collectively and together with the Inventions, the "Proprietary Rights"), shall be the sole and
    exclusive property of the Company, its successors and assigns (for the purposes of this Section 2, collectively, the "Company").
    All works authored by me pursuant to the Agreement, including without limitation the Inventions, shall be deemed "work
    made for hire".

 

	2.2.	I
    shall have no title, rights, claims or interest whatsoever in or with respect to the Proprietary Rights. I hereby acknowledge
    and agree that the Monthly Fee I am entitled to receive from the Company constitutes the sole and exclusive consideration
    to which I am entitled, by virtue of any contract or law (including, but not limited to, the Israel Patent Law, 5727-1967
    (the "Patent Law")), in respect of any and all Inventions, and I hereby waive all past, present and future
    demands, contentions, allegations or other claims, of any kind, in respect thereof, including the right to receive any additional
    royalties, consideration or other payments.  Without derogating from the aforesaid, I hereby acknowledge and agree that
    the level of the compensation and consideration to which I am entitled has been established based upon the aforementioned
    waiver of rights to receive any such additional royalties, consideration or other payment. The foregoing will apply to any
    "Service Inventions" as defined in the Patent Law and under no circumstances will I be deemed to have any proprietary
    right in any such Service Invention, notwithstanding the provision or non-provision of any notice of an invention and/or company
    response to any such notice, under Section 132(b) of the Patent Law. This Undertaking and the Agreement are expressly
    intended to be an agreement with regard to the terms and conditions of consideration for Service Inventions in accordance
    with Section 134 of the Patent Law.

 

    Annex B-2

     

    

 

	2.3.	I
    hereby irrevocably and unconditionally transfer and assign to the Company, and if and when not otherwise assignable herein,
    agree and undertake to transfer and assign to the Company in the future, any and all of my rights, title and interest, now
    and hereafter acquired, in and to the Proprietary Rights, (without any payments, liabilities or restrictions to any person
    or third party) in any and all media now known or hereafter devised, and all claims and causes of action of any kind with
    respect to any of the foregoing, throughout the world in perpetuity.

 

In
the event that pursuant to any applicable law I retain any rights in and to the Proprietary Rights that cannot be assigned to
the Company, I hereby unconditionally and irrevocably waive any right, claim or demand with respect thereto (including without
limitation for any compensation, royalty or reward, or the enforcement of all such rights), and all claims and causes of action
of any kind with respect to any of the foregoing, and agree, at the request and expense of the Company, to consent to and join
in any action to enforce such rights and to procure a waiver of such rights from the holders of such rights, if any.

 

In
the event that I retain any rights in and to Proprietary Rights that cannot be assigned to the Company and cannot be waived, I
hereby grant the Company an irrevocable, exclusive, perpetual, worldwide, royalty-free license to exploit, use, develop, perform,
modify, change, reproduce, publish and distribute, with the right to sublicense and assign such rights, and all claims and causes
of action of any kind with respect to any of the foregoing, in and to the Proprietary Rights, in any way the Company sees fit
and for any purpose whatsoever. Without derogating from the above, I hereby forever waive and agree never to assert any and all
rights of paternity or integrity, any right to claim authorship of any Invention, to object to any distortion, mutilation or other
modification of, or other derogatory action in relation to any Invention, and any similar right.

 

	2.4.	I
    will promptly disclose to the Company fully and in writing all Inventions but will otherwise keep the Inventions in strict
    confidence in accordance with the provisions of Section 1 above.

 

	2.5.	I
    further agree and undertake to take all necessary measures and to fully cooperate with the Company, during and after the term
    of my engagement, in order to perfect, enforce, and/or defend the Proprietary Rights, and effectuate the Company's title and
    interest therein, including without limitation as follows: (i) to keep accurate records relating to the conception
    and reduction to practice of all Proprietary Rights, which records shall be the sole and exclusive property of the Company
    and shall be surrendered to the possession of the Company, immediately upon their creation; and (ii) to provide the Company
    with all information, documentation, and assistance, including the preparation or execution, as applicable, of documents,
    declarations, assignments, drawings and other data, all such information, documentation, and assistance to be provided at
    no additional expense to the Company, except for out-of-pocket expenses incurred by me at the Company's request or with the
    Company's prior written consent. Without derogating from any of my obligations hereunder, I hereby appoint any officer of
    the Company as my duly authorized agent to execute, file, prosecute and protect the same before any government agency, court
    or authority.

 

	3.	Non-Competition;
    NON-SOLICITATION

 

	3.1.	I
    agree and declare that, so long as I am an service provider of the Company, and for a period of six (6) months following termination
    of my engagement, I will not, directly or indirectly, (i) engage in, participate, assist or become financially interested
    in, any business venture worldwide that is engaged in any activity competing with Company's business; (ii) employ or otherwise
    engage, recruit or otherwise solicit, induce or influence any person to leave the employment or service of the Company; and
    (iii) solicit or encourage any customer, supplier or service provider to terminate or modify adversely its business relationship
    with the Company or otherwise intervene in any relationship between the Company and any of its employees, contractors, suppliers
    or consultants.

 

    Annex B-3

     

    

 

For
the purposes of this Section ‎3, "directly or indirectly" includes doing business as an owner, partner,
joint venturer, an independent contractor, shareholder, director, officer, manager, broker, agent, employee, service provider
or advisor, licensor or in any other capacity whatsoever, but does not include holding up to 1% of the free market shares of any
publicly traded companies.

 

	3.2.	I
    hereby acknowledge that the provisions of this Section ‎3 are reasonable to legitimately protect Confidential Information,
    Proprietary Rights and Company property (including intellectual property and goodwill) to which I, in my position in the Company,
    have been and will continue to be exposed, and that my compensation under the Agreement incorporates special consideration
    with respect for these non-competition undertaking.

 

	4.	General

 

	4.1.	The
    undersigned understands and agrees that monetary damages would not constitute a sufficient remedy for any breach or default
    of the obligations contained in this Undertaking, and that the Company shall be entitled, without derogating from any other
    remedies, to seek injunctive or other equitable relief to remedy or forestall any such breach or default or threatened breach.

 

	4.2.	The
    provisions of the Agreement relating to term and termination and the general provisions thereof shall apply to this Undertaking,
    mutatis mutandis.

 

In
witness whereof, I hereby affix my name and
signature, on this __ day of November 2015.

 

	/s/ Mr. Guy Goldin	 
	Mr.
Guy Goldin	 

 

    Annex B-4

     

    

 

 

Execution
Copy

 

1st
Amendment Of Financial Services Agreement

 

This 1st Amendment (the "Amendment")
is made and entered into on this 22 day of March, 2016, by and between Therapix Biosciences Ltd., a public company organized
under the laws of the State of Israel (the "Company"), and Mr. Guy Goldin, ID no. 029410768 (the “Contractor”).
The Company and the Contractor may be referred to collectively as the “Parties” and each as a “Party”

 

	WHEREAS	the Company and the Contractor have entered into a Financial Services Agreement, dated November 30, 2015 (the "Agreement"); and

 

	WHEREAS	pursuant to section 1.7 of the Agreement, the Parties desire to amend the Agreement as further set forth herein.

 

NOW THEREFORE, in consideration of the
mutual promises contained herein, and intending to be legally bound, the parties hereby declare and agree as follows:

 

	1.	Capitalized terms used and not otherwise defined herein shall bear the respective meanings ascribed to them in the Agreement.

 

	2.	Effective as of April 1, 2016:

 

	 	2.1.	Contractor shall act as the Company's Chief Financial Officer and Company’s secretary. Annex A of the Agreement shall be deemed to have been amended with the necessary changes, to reflect said change of position.

 

	 	2.2.	Notwithstanding anything to the contrary in section 1.7 of the Agreement, Contractor shall devote up to 87 hours per month for the ongoing work and additional up to 45 hours per quarter for the performance of the Services (which together represent in practice the scope of approx. 55% of full time position) (The “Increase in Services Hours”)

 

	3.	In consideration for the Increase in Services Hours, Contractor has agreed to be compensated with an option to purchase up to 150,000 Ordinary Shares of the Company, par value NIS 0.01 each, which terms shall be determined by the Company’s Compensation Committee and Board of Directors, and as further detailed under the Option Agreement attached hereto as Annex A (the “Option Agreement”).

 

	4.	Contractor understand and agrees that he (or any agent, representative, counsel, successor, and any third party which he is or will be engaged with, including without limitation, Baseline) shall not be entitled to any additional consideration pursuant to the Increase in Services Hours (including, without derogating from the generality of the aforementioned, any cash or cash-equivalent compensation of any kind).

 

	5.	The Agreement, as amended hereby, shall continue in full force and effect as originally constituted and is hereby ratified and affirmed by the Parties. Any contradiction in meaning and/or interpretation between the Agreement and this Amendment shall have the meaning and/or be interpreted in light of this Amendment.

  

[Signature Page to Follow]

 

     

     

    

 

Execution
Copy

 

IN WITNESS WHEREOF, the parties have duly executed
this Amendment as of the date first written above.

 

	/s/
    Guy Goldin	 	/s/
    Elran Haber	 	/s/ Ascher Shmulewitz
	Guy Goldin 
	 	Therapix Biosciences Ltd.

	 	 	 	 	 
	 	 	By:	Elran Haber	 	Ascher Shmulewitz
	 	 	 	 	 	 
	 	 	Title:	CEO	 	Chairman

  

     

     

    

 

Execution
Copy

 

Annex A

Option Agreement

 

This
Option Agreement, made this 5th day of May, 2016, by and between Therapix
Biosciences Ltd., a public company incorporated under the laws of the State of Israel, of 5
Azrieli Center Square Tower 27th Fl., Tel-Aviv 6702501, Israel (the "Company"),
and Guy Goldin, ID No. 029410768,
of ____________ (the "Optionee").

 

WHEREAS,
on December 17, 2015, the Company duly adopted and the Board approved Company’s 2015 Share Option Plan, a copy of which
attached hereto as Exhibit A, forming an integral part hereof (the “Plan”);
and 

 

WHEREAS,
pursuant to the Plan, the Company has decided on March 22, 2016, to grant the Optionee an Option to purchase Shares of the Company
to the Optionee, and the Optionee has agreed to such grant, subject to all the terms and conditions as set forth in the Plan and
as provided herein.

 

NOW,
THEREFORE, it is agreed as follows:

 

1.            Preamble
and Definitions. The preamble to this Option Agreement constitutes an integral part hereof.
Unless otherwise defined herein, capitalized terms used herein shall have the meaning ascribed to them in the Plan.

 

2.            Grant
of Options.

 

2.1            The
Company hereby grants to the Optionee or the Trustee (in the case of grants designated as grants made through a trustee pursuant
to Section 102 (a "102 Option"))
an option to purchase such number of Shares as set forth in Exhibit B hereto (the
"Option"); upon payment of the Option Exercise Price (as set forth in Exhibit
B), subject to the terms and the conditions as set forth in the Plan and as provided herein.

 

2.2            The
Optionee is aware that the Company intends in the future to issue additional shares and to grant additional options to various
entities and individuals, as the Company in its sole discretion shall determine.

 

2.3            The
issuance of the Option is subject to the approval of the Tel Aviv Stock Exchange Ltd. ("TASE")
to the registration for trade of the shares resulting from the exercise of the Option.  

 

3.            Period
of Option and Conditions of Exercise.

 

3.1            The
Option Agreement shall commence on the Date of Grant and terminate 10 (ten) years thereafter, as specified in Exhibit B
hereto, or at such time on which the Option expires pursuant to the terms of the Plan or this Option Agreement, unless determined
otherwise by the Board of Directors of the Company (the "Expiration
Date"). 

 

3.2            The
Option may be exercised only to purchase whole Shares, and in no case may a fraction of a Share be purchased. If any fractional
Share would be deliverable upon exercise, such fraction shall be rounded up one-half or less, or otherwise rounded down, to the
nearest whole number.

 

4.            Adjustments.

 

4.1            Notwithstanding
anything to the contrary in Section 9.1 of the Plan and in addition thereto, if in any such Transaction as described in Section
9.1 of the Plan, the Successor Company (or parent or subsidiary of the Successor Company) does not agree to assume or substitute
for the Option, the Vesting Dates shall be accelerated so that any unvested Option or any portion thereof shall be immediately
vested as of the date which is ten (10) days prior to the effective date of the Transaction.

 

4.2            The
number of Shares purchasable upon the exercise of this Option and the payment of the Option Exercise Price shall be subject to
adjustment from time to time or upon exercise as provided in this Section 4.

 

    	 	 	 

     

    

 

5.            Vesting;
Period of Exercise. 

 

5.1            Subject
to the provisions of the Plan, Options shall vest and become exercisable according to the Vesting Dates set forth in
Exhibit B hereto, provided that there
has not been termination of Optionee’s employment or services with the Company and/or its Affiliates on the applicable Vesting
Date.

 

5.2            All
unexercised Options granted to the Optionee shall terminate and shall no longer be exercisable on the Expiration Date.

 

6.            Exercise
of Options. 

 

6.1            Options
may be exercised in accordance with the provisions of Section 10.1 of the Plan and subject to the directives of the TASE.

 

6.2            In
order for the Company to issue Shares upon the exercise of any of the Options, the Optionee hereby agrees to sign any and all
documents required by any applicable law and/or by the Company's incorporation documents or by the Company or the Trustee. The
Optionee further agrees that in the event that the Company and its counsel deem it necessary or advisable, in their sole discretion,
the issuance of Shares may be conditioned upon certain representations, warranties, and acknowledgments by the Optionee.

 

6.3            Pursuant
to Section 6.5 and 6.6 of the Plan and, when applicable, subject to the provisions of Section 102, any Shares acquired upon the
exercise of the Option shall be voted by an Irrevocable Proxy and Power of Attorney, attached hereto as Exhibit
C. 

 

6.4            The
Company shall not be obligated to issue any Shares upon the exercise of an Option if such issuance, in the opinion of the Company,
might constitute a violation by the Company of any provision of law.

 

7.            Restrictions
on Transfer of Options and Shares. 

 

7.1            The
transfer of Options and the transfer of Shares to be issued upon exercise of the Options shall be subject to the limitations set
forth in the Plan and in the Company’s incorporation documents, or in any applicable law including securities law of any
jurisdiction.

 

7.2            The
Optionee shall not dispose of any Shares in transactions, which violate, in the opinion of the Company, any applicable laws, rules
and regulations. 

 

7.3            The
Optionee agrees that the Company shall have the authority to endorse upon the certificate or certificates representing the Shares
such legends referring to the foregoing restrictions, and any other applicable restrictions as it may deem appropriate (which
do not violate the Optionee's rights according to this Option Agreement).

 

7.4            With
respect to any 102 Option, subject to the provisions of Section 102 and any rules or regulation or orders or procedures promulgated
thereunder, an Optionee shall not sell or release from trust any Share received upon the exercise of an 102 Option and/or, as
the case may be, any share received subsequently following any realization of rights and any additional rights issued in respect
of the 102 Option or shares received subsequently, including without limitation, bonus shares, until the lapse of the Lock-Up
Period required under Section 102, as shall be in effect from time to time. Notwithstanding the above, if any such sale or release
occurs during the Lock-Up Period, the sanctions under Section 102 and under any rules or regulation or orders or procedures promulgated
thereunder shall apply to and shall be borne by such Optionee.

 

8.            Taxes;
Indemnification. 

 

8.1            Any
tax consequences arising from the grant or exercise of any Option, from the payment for Shares covered thereby or from any other
event or act (of the Company and/or its Affiliates, the Trustee or the Optionee), hereunder, shall be borne solely by the Optionee.
The Company and/or its Affiliates and/or the Trustee shall withhold taxes according to the requirements under the applicable laws,
rules, and regulations, including withholding taxes at source. Furthermore, the Optionee hereby agrees to indemnify the Company
and/or its Affiliates and/or the Trustee and hold them harmless against and from any and all liability for any such tax or interest
or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any
such tax from any payment made to the Optionee.

 

    	 	 	 

     

    

 

8.2            The
Optionee will not be entitled to receive from the Company and/or the Trustee any Shares allocated or issued upon the exercise
of Options and any additional rights issued in respect of the 102 Option or shares received subsequently, including without limitation,
bonus shares prior to the full payments of the Optionee’s tax liabilities arising from Options which were granted to him
and/or Shares issued upon the exercise of Options. For the avoidance of doubt, neither the Company or the Trustee shall not be
required to release any share certificate to the Optionee until all payments required to be made by the Optionee have been fully
satisfied. 

 

8.3            The
receipt of the Options and the acquisition of the Shares to be issued upon the exercise of the Options may result in tax consequences.
The Optionee is advised
to consult a tax adviser with respect to the tax consequences of receiving or exercising this Option or disposing of the Shares.

 

8.4            With
respect to Approved 102 Options, the Optionee hereby acknowledges that Optionee is familiar with the provisions of Section 102
and the regulations and rules promulgated thereunder, including without limitations the type of Option granted hereunder and the
tax implications applicable to such grant. The Optionee accepts the provisions of the trust agreement signed between the Company
and the Trustee, attached hereto as Exhibit
D, and agrees to be bound by its terms, including, without derogating of the aforementioned,
not to exercise the Shares except for as prescribed under Section 102.

 

9.            Miscellaneous

 

9.1            No
Obligation to Exercise Options. The grant and acceptance of these Options imposes no obligation on the Optionee to exercise
it.

 

9.2            Confidentiality.
The Optionee shall regard the information in this Option Agreement and its exhibits attached hereto as confidential information
and the Optionee shall not reveal its contents to anyone except when required by law or for the purpose of gaining legal or tax
advice.

 

9.3            Continuation
of Service. Neither the Plan nor this Option Agreement shall impose any obligation on the Company or an Affiliate to continue
the Optionee’s employment and nothing in the Plan or in this Option Agreement shall confer upon the Optionee any right to
continue in the service of the Company and/or an Affiliate or restrict the right of the Company or an Affiliate to terminate such
service at any time.

 

9.4            Entire
Agreement. Subject to the provisions of the Plan, to which this Option Agreement is subject, this Option Agreement, together
with the exhibits hereto, constitute the entire agreement between the Optionee and the Company with respect to Options granted
hereunder, and supersedes all prior agreements, understandings and arrangements, oral or written, between the Optionee and the
Company with respect to the subject matter hereof.

 

9.5            Failure
to Enforce. Not a Waiver. The failure of any party to enforce at any time any provisions of this Option Agreement or the
Plan shall in no way be construed to be a waiver of such provision or of any other provision hereof.

 

9.6            Interpretation.
Any interpretation of this Option Agreement will be made in accordance with the Plan but in the event there is any contradiction
between the provisions of this Option Agreement and the Plan, the provisions of this Option Agreement will prevail.

 

9.7            Binding
Effect. This Option Agreement shall be binding upon the heirs, executors, administrators and successors of the parties
hereof.

 

9.8            Notices.
All notices or other communications given or made hereunder shall be in writing and shall be delivered or mailed by registered
mail or delivered by email or facsimile with written confirmation of receipt to the Optionee and/or to the Company at the addresses
shown on the letterhead above, or at such other place as the Company may designate by written notice to the Optionee. The Optionee
is responsible for notifying the Company in writing of any change in the Optionee’s address, and the Company shall be deemed
to have complied with any obligation to provide the Optionee with notice by sending such notice to the address indicated below.

 

    	 	 	 

     

    

 

	/s/
    Therapix     Biosciences Ltd	 
	Therapix
    Biosciences Ltd.	 
	Name:
    	Elran
    Haber 	 
	Title:
    	CEO	 

 

I,
the undersigned, hereby acknowledge receipt of a copy of the Plan and accept the Option subject to all of the terms and provisions
thereof. I have carefully read and reviewed the Plan and this Option Agreement in its entirety, have had an opportunity to obtain
the advice of counsel prior to executing this Option Agreement, and fully understand all provisions of the Plan and this Option
Agreement. I agree to notify the Company upon any change in the residence address indicated above.

 

Furthermore,
I hereby declare and agree that:

 

All
prior agreements, arrangements and/or understandings with respect to shares of the Company or options to purchase shares of the
Company which have not actually been issued or granted prior to execution of the Agreement shall be null and void and that only
the provisions of the Plan and/or the Agreement shall apply.

 

I
am not a "Controlling Shareholder" as defined in Section 32(9) of the Income Tax Ordinance, and shall not be one after
the option allocation.

 

I
will inform the Trustee at the end of each year whether I am an Israeli resident.

 

I
am obligated to provide any additional document and to sign any additional document or declaration required by the Trustee or
the Company.

 

	 /s/
    Guy Goldin	 
	Optionee	 
	Name:
    Guy Goldin	 

 

    	 	 	 

     

    

 

EXHIBIT
A

2015
SHARE OPTION PLAN

 

 

 

 

 

 

 

 

 

 

    	 	 	 

     

    

 

EXHIBIT
B

TERMS
OF THE OPTION

 

	Name
    of the Optionee:	Guy
    Goldin
	 	 
	Date
    of Grant:	March
    22, 2016
	 	 
	Designation:

        

        (Please
check the relevant box)
	☒
                                                         102                                          Option - Capital Gain Option (CGO)

        

        ☐
        3(i) Option

        

        ☐
        other

	 	 
	Number
    of Options granted:	150,000
	 	 
	Exercise
    Price:            	NIS
                                         1.011

         

	Vesting
    Dates:	The
                                         Option shall vest over a three (3) year period, on a quarterly basis, such that 1/12
                                         Shares shall vest upon the end of each quarter commencing on the Date of Grant.

         

	Expiration
    Date	February
    16, 2026, subject to prior expiration as prescribed under the terms of the Plan.

 

    	 	 	 

     

    

 

EXHIBIT
C

IRREVOCABLE
PROXY AND POWER OF ATTORNEY

 

I,
the undersigned, Guy Goldin, hereby appoint Meitav Dash Trusts Ltd. or whomever shall replace it as trustee pursuant to Therapix
Biosciences Ltd.’s (the "Company") 2015 Share Option Plan (the "Trustee" and the "Plan",
respectively) or whomever the Trustee shall designate (the Trustee and/or such designee shall be referred to hereafter as the
"Attorney") as my proxy to participate and vote (or abstain) for me and on my behalf as the Attorney at his sole
discretion shall deem appropriate, on all matters and at all meetings of shareholders (whether ordinary, extraordinary or otherwise)
of the Company, on behalf of all the shares and/or options of the Company held by the Trustee on my behalf and hereby authorize
and grant a power of attorney to the Attorney as follows:

 

I
hereby authorize and grant power of attorney to the Attorney for as long as any shares and/or options which were allotted or granted
on my behalf are held by the Trustee or registered in his name, or for as long as the certificates representing any shares are
held by the Trustee, to exercise every right, power and authority with respect to the shares and/or options and to sign in my
name and on my behalf any document (including any agreement, including a merger agreement of the Company or an agreement for the
purchase or sale of assets or shares (including the shares of the Company held on my behalf) and any and all documentation accompanying
any such agreements, such as, but not limited to, resolutions, decisions, requests, instruments, receipts and the like), and any
affidavit or approval with respect to the shares and/or options or to the rights which they represent in the Company in as much
as the Attorney shall deem it necessary or desirable to do so. In addition and without derogating from the generality of the foregoing,
I hereby authorize and grant power of attorney to the Attorney to sign any document as aforesaid and any affidavit or approval
(such as any waiver of rights of first refusal to acquire shares which are offered for sale by other shareholders of the Company
and/or any waiver of any preemptive rights to acquire any shares being allotted by the Company, in as much as such rights shall
exist pursuant to the Company’s Articles of Association as shall be in existence from time to time) and/or to make and execute
any undertaking in my name and on my behalf if the Attorney shall, at his sole discretion, deem that the document, affidavit or
approval is necessary or desirable for purposes of any placement of securities of the Company, whether private or public (including
lock-up and/or market stand-off arrangements and undertakings), whether in Israel or abroad, for purposes of a merger of the Company
with or into another entity, whether the Company is the surviving entity or not, for purposes of any reorganization or recapitalization
of the Company or for purposes of any purchase or sale of assets or shares of the Company.

 

This
Proxy and Power of Attorney shall be interpreted in the widest possible sense, in reliance upon the Plan and upon the goals and
intentions thereof.

 

This
Proxy and Power of Attorney shall be irrevocable until such time as the rights of the Company and the Company’s shareholders
are dependent hereon. The revocation of this Proxy and Power of Attorney shall in no manner effect the validity of any document
(as aforesaid), affidavit or approval which has been signed or given as aforesaid prior to the revocation hereof and in accordance
herewith.

 

    	 	 	 

     

    

 

This
Proxy and Power of Attorney shall also apply to all shares and/or options in other entities issued or granted to or on behalf
of the undersigned and held by the Trustee in consideration or in exchange for, or by virtue of, any shares and/or options of
the Company in connection with any consolidation, merger, spin-off or like transaction with respect to the Company, and the term
“Company” when used herein shall include any other such entity.

 

IN
WITNESS WHEREOF, I have executed this Proxy and Power of Attorney on the 5th day of May 2016.

 

	 /s/
    Guy Goldin	 
	Name:
    Guy Goldin	 

 

I.D.
Number: 029410768

 

CONFIRMATION

 

I,
the undersigned, Elran Haber hereby confirm the signature of Guy Goldin which appears above.

 

/s/
Elran Haber                                                      

 

    	 	 	 

     

    

 

EXHIBIT
D

TRUST
AGREEMENT

 

(unofficial translation from Hebrew original)

Executed in Tel Aviv on the 17 day
of December, 2015 

	Between:		Meitav Dash Mutual
    Funds Ltd.
	 	 	Derech Sheshet Hayamim
    30, Bnei Brak
	 	 	(Hereinafter - the
    “Trustee”)                                                                                  One
    side

 

 

 

	And:		Therapix Biosciences
    Ltd.
	 	 	I.D. 513581652
	 	 	(Hereinafter - the
    “Company”)                                                                            Second
    side

 

RECITALS

 

	WHEREAS	On the date December 17, 2015 the Company adopted an employee stock option plan, as defined in
section 102 of the ordinance (the "Plan");
	 	 	 

	WHEREAS	According to the Plan, the company will allocate, from time to time, shares or options for Company
employees, executives, and consultants (together, the "Employees") by means of a trustee;
	 	 	 

	WHEREAS	According to the Plan, the shares will be allocated to the Trustee so that it may hold the shares
in a trust until the end of the exercise period of the allocated shares, as mentioned in the ordinance, the Income Tax Rules (Tax
Breaks in Employee Stock Allocation), 5763 – 2003 (the "Rules"), in the Plan, and in this trust agreement;
	 	 	 

	WHEREAS	The Company chose Meitav Dash Mutual Funds Ltd. to act in trust on behalf of the Company for all
option and share allocations deriving from the Plan and the Trustee has given its approval to serve as a trustee for all employed
companies and their employees;

 

NOW, THEREFORE, the Parties hereto agree
as follows:

	1.	The recitals to this agreement are an integral and inseparable part
of the agreement.
	 	 	 
	2.	According to the Plan, Company shares will not be allocated rather
the said shares will be allocated under the name of the Trustee and be held by the Trustee until the end of the time period, as
defined in section 102 of the ordinance.
	 	 	 
	3.	Before the tax that applies is paid as stated in section 7 of the
Rules, the shares will not be available for transfer, assignation, mortgage, foreclosure, or any other lien by will and due to
the aforementioned no power of attorney or deed transfer will be given, regardless of whether it is to expire immediately or at
a future date, except for a transfer deriving from a will or by law; 

 

     

     

    

 

If shares are
transferred in accordance with a will or by law, as mentioned above, the stated in clause 102 and the Rules will apply to the inheritance
or transferees of the employee.

 

	4.	After the end of the holding period, every employee may request at
any time that the Transferee transfer the allocated shares under his/her name, provided that the Transferee does not transfer the
said shares until after such time that the applied tax from section 102 is paid and in accordance with the Rules (the "Applied
Tax") and the Trustee holds in its possession approval of the Applied Tax from the tax official.
	 	 	 
	5.	If according to the terms of the Plan, options are allocated to the
employee or in consideration with the held shares, preferred shares are allocated to the employee, the respective options or preferred
shares shall be allocated under the Trustee's name. The employee shall be entitled to instruct the Trustee to fulfill the right
granted by the options or to realize the preferred shares after the expiration of the time period set forth in the Plan. Shares
subject to the rights shall be allocated to the Trustee in accordance with the stated in section 2 of the Rules, and the contents
of the Plan will apply to them, including choice of tax track and the instructions of this trust agreement, however the time period
until expiration shall be counted commencing from the day the shares were allocated, respect of which the options or preferred
shares were granted.
	 	 	 
	6.	The Company guarantees to the Trustee that no shares will be allocated
to employees in accordance with the Plan, if the employee has not declared that the instructions of clause 102 of the ordinance
and the tax path that applies are known to him/her, and that he/she agrees to the stated contents of this trust agreement and to
the commitment not to realize the shares before the end of the time period, as defined in section 102 of the ordinance.

 

In Witness Whereof the Parties
hereto have set their hands:

 

	/s/ Meitav Dash Mutual Funds Ltd.	      /s/ Therapix Biosciences Ltd.
	The Trustee	      The Company

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]